focus -WSS

focus

author：leisure time 2025-10-02 19:21:16 - browse：8214

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： My chronic pain journey would have been easier knowing 5 things % STAT

hotspot

WSS

The response to Covid

Make 'food is medicine' a key part of White House nutrition meeting

Transgender women dream of pregnancy via uterus transplants

Meta looks to target Twitter with a rival app called Threads

4 missing after record

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

focus

focus

focus

Supreme Court strikes down use of affirmative action

How to protect coverage of PrEP

George Santos makes 1st court appearance after pleading not guilty to 13 counts

RaDonda Vaught case: a double standard for nurses, physicians

Medicare proposal to cover medical devices draws a mixed reaction

Did the public have the right to know Arthur Ashe had AIDS?

23andMe had bad news about my health. I wish a person had delivered it

Doctors have an ethical obligation to be advocates

In Memoriam: Notable people who died in 2023

Option Care buys Amedisys in $3.6 billion home care deal

hotspot

Severe heat forecast: Where scorching temperatures will persist over the next week

Sophia Smith scores twice for US in in 3

A new study asks: Are we harming blood donors by taking blood?

Men with early prostate cancer can safely opt out of treatment

Pfizer's Covid pill remains 89% effective in final analysis, company says

Meta looks to target Twitter with a rival app called Threads

focus

hotspot

hotspot

hotspot